ASX ANNOUNCEMENT Actinogen pivotal Alzheimer’s disease trial demonstrates trends toward clinical benefit in older patients and favourable longer term safety profile Sydney, 19 November 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) today announces ® topline results from its...
ACW XanaMIA Alzheimers trial results
Filed with ASX · · 19 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced the topline results from its pivotal XanaMIA trial, which evaluated the efficacy of Xanamem in treating Alzheimer's disease in older patients. Xanamem was found to be safe and well tolerated over the treatment period, with a favorable longer-term safety profile. The company plans to continue the Open Label Extension phase of the trial to gather additional data on disease stabilization.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Suspension from Quotation
- Request for Trading Halt
- Trading Halt
- Notification of cessation of securities - ACW
- Update - Notification of buy-back - ACW
Later from Actinogen Medical
All Actinogen Medical news releasesFollow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical